Libtayo® (cemiplimab) recommended for eu approval by the chmp for adjuvant treatment of cutaneous squamous cell carcinoma (cscc) with a high risk of recurrence after surgery and radiation

Positive opinion based on results of phase 3 c-post trial that show libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p

REGN Ratings Summary

REGN Quant Ranking